Sanofi to Acquire Vigil Neuroscience, Expanding Alzheimer's Treatment Pipeline with VG-3927

Reuters

2025/05/22

<a href="https://laohu8.com/S/GCVRZ">Sanofi</a> to Acquire Vigil Neuroscience, Expanding Alzheimer's Treatment Pipeline with VG-3927

Sanofi SA has announced an agreement to acquire Vigil Neuroscience, Inc., a clinical-stage biotechnology company specializing in therapies for neurodegenerative diseases. This acquisition will bolster Sanofi's neurology pipeline by introducing VG-3927, an investigational medicine aimed at treating Alzheimer's disease. The transaction is valued at approximately $470 million, with Vigil's shareholders receiving $8 per share in cash and a contingent value right for an additional $2 per share, dependent on the first commercial sale of VG-3927. The deal is expected to close in the third quarter of 2025, aligning with Sanofi's strategic focus on innovation in critical healthcare areas. Notably, VGL101, another molecule program from Vigil, will not be part of this acquisition.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001098215-en) on May 21, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2537957291"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537957291\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2537957291?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-22 07:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537957291","market":"us","top_or_hot":-1,"title":"Sanofi to Acquire Vigil Neuroscience, Expanding Alzheimer's Treatment Pipeline with VG-3927","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> to Acquire Vigil Neuroscience, Expanding Alzheimer's Treatment Pipeline with VG-3927\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> SA has announced an agreement to acquire <a href=\"https://laohu8.com/S/VIGL\">Vigil Neuroscience, Inc.</a>, a clinical-stage biotechnology company specializing in therapies for neurodegenerative diseases. This acquisition will bolster Sanofi's neurology pipeline by introducing VG-3927, an investigational medicine aimed at treating Alzheimer's disease. The transaction is valued at approximately $470 million, with Vigil's shareholders receiving $8 per share in cash and a contingent value right for an additional $2 per share, dependent on the first commercial sale of VG-3927. The deal is expected to close in the third quarter of 2025, aligning with Sanofi's strategic focus on innovation in critical healthcare areas. Notably, VGL101, another molecule program from Vigil, will not be part of this acquisition.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001098215-en) on May 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi to Acquire Vigil Neuroscience, Expanding Alzheimer's Treatment Pipeline with VG-3927</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi to Acquire Vigil Neuroscience, Expanding Alzheimer's Treatment Pipeline with VG-3927\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-22 07:15</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> to Acquire Vigil Neuroscience, Expanding Alzheimer's Treatment Pipeline with VG-3927\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> SA has announced an agreement to acquire <a href=\"https://laohu8.com/S/VIGL\">Vigil Neuroscience, Inc.</a>, a clinical-stage biotechnology company specializing in therapies for neurodegenerative diseases. This acquisition will bolster Sanofi's neurology pipeline by introducing VG-3927, an investigational medicine aimed at treating Alzheimer's disease. The transaction is valued at approximately $470 million, with Vigil's shareholders receiving $8 per share in cash and a contingent value right for an additional $2 per share, dependent on the first commercial sale of VG-3927. The deal is expected to close in the third quarter of 2025, aligning with Sanofi's strategic focus on innovation in critical healthcare areas. Notably, VGL101, another molecule program from Vigil, will not be part of this acquisition.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001098215-en) on May 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2095319765.USD","symbol_name":"Natixis Thematics Subscription Economy R/A USD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nNDL80jzys:1","article_id":"2537957291","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537957291","pubTimestamp":1747869335,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sanofi SA has announced an agreement to acquire Vigil Neuroscience, Inc., a clinical-stage biotechnology company specializing in therapies for neurodegenerative diseases. This acquisition will bolster Sanofi's neurology pipeline by introducing VG-3927, an investigational medicine aimed at treating Alzheimer's disease. The transaction is valued at approximately $470 million, with Vigil's shareholders receiving $8 per share in cash and a contingent value right for an additional $2 per share, dependent on the first commercial sale of VG-3927. The deal is expected to close in the third quarter of 2025, aligning with Sanofi's strategic focus on innovation in critical healthcare areas. Notably, VGL101, another molecule program from Vigil, will not be part of this acquisition.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purp","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4139":"生物科技","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","VIGL":"Vigil Neuroscience, Inc.","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4585":"ETF&股票定投概念","BK4588":"碎股","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4112":"金融交易所和数据","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所"},"translate_title":"赛诺菲将收购Vigil Neuroscience，通过VG-3927扩大阿尔茨海默病治疗产品线","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VIGL":0.9,"NDAQ":0.9},"content_text":"Sanofi to Acquire Vigil Neuroscience, Expanding Alzheimer's Treatment Pipeline with VG-3927\n    \n\nSanofi SA has announced an agreement to acquire Vigil Neuroscience, Inc., a clinical-stage biotechnology company specializing in therapies for neurodegenerative diseases. This acquisition will bolster Sanofi's neurology pipeline by introducing VG-3927, an investigational medicine aimed at treating Alzheimer's disease. The transaction is valued at approximately $470 million, with Vigil's shareholders receiving $8 per share in cash and a contingent value right for an additional $2 per share, dependent on the first commercial sale of VG-3927. The deal is expected to close in the third quarter of 2025, aligning with Sanofi's strategic focus on innovation in critical healthcare areas. Notably, VGL101, another molecule program from Vigil, will not be part of this acquisition.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001098215-en) on May 21, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}